AstraZeneca paid US$100 million in upfront cash for JAB-23E73, a single pan-KRAS inhibitor that has not left Phase I. At HK$7.22, buying all of Jacobio costs approximately US$730 million. Subtract HK$1.73 billion in net cash, and the market values everything that remains — an approved drug, a Phase III trial, and US$1.9 billion in AZ milestones — at US$507 million. The discount is documentable. The reason it exists is commercial uncertainty, not scientific failure.
AstraZeneca had a choice. In late 2025, they paid US$100 million — upfront, in cash — for a single molecule: JAB-23E73, a pan-KRAS inhibitor that has not yet left Phase I. They did not pay that sum for Jacobio's approved drug. They did not pay it for Jacobio's cash. They paid it for one early-stage candidate.
At today's price of HK$7.22, buying all of Jacobio costs approximately US$730 million. After subtracting HK$1.73 billion in net cash already in the accounts, the market values everything that remains at US$507 million. One approved KRAS inhibitor, listed on China's national reimbursement system. A Phase III trial underway. The same pipeline AZ just wrote a nine-figure check to access.
That arithmetic deserves a second look.
What Jacobio Does
This is not a startup chasing a mechanism. Jacobio Pharmaceuticals has built its franchise around one mutation — KRAS G12C — that drives a subset of non-small cell lung cancer. Their lead product, glecirasib, blocks that mutation. It received approval from China's National Medical Products Administration and was included on China's National Reimbursement Drug List — the NRDL — in late 2024.
NRDL inclusion is the equivalent of national formulary listing: it opens hospital procurement across all of China simultaneously. Before that listing, glecirasib could only reach patients willing to pay out of pocket. After it, the drug becomes accessible to any eligible patient in any public hospital in China. That is the starting gun for volume.
In parallel, Jacobio is running a Phase III study combining glecirasib with a PD-1 inhibitor for first-line treatment of KRAS G12C NSCLC. If that trial succeeds, the addressable patient population expands substantially — from second-line salvage to front-line standard of care, where volumes are three to five times larger.
Why the Market Is Where It Is
Two facts keep the stock where it is, and neither should be dismissed.
First, Jacobio is pre-profit. The first commercial year for glecirasib — seven months of NRDL-listed sales through December 2025 — generated RMB 8.55 million. At that run rate, the drug is reaching 250 to 400 patients per month in a market that can theoretically absorb tens of thousands per year. Penetration is below 1%. That number is difficult to read without context: it is either the beginning of an exponential ramp, or evidence that hospital adoption is slower than the model assumed.
Second, KRAS G12C is less prevalent in Asian patients — 8 to 10% of Chinese NSCLC cases — than in Western cohorts, where the mutation appears in 13% of patients. The total addressable market in China is smaller than the early projections suggested. The market has incorporated that correction.
The discount exists for a documented reason. The question is whether that correction has overshot.
Three Facts Operating Simultaneously
Most market participants have processed one of these. All three are in play at the same time.
- 01 AstraZeneca's payment is a data point, not a press release. US$100 million in upfront cash for JAB-23E73 — before a pivotal trial has read out, before any regulatory filing outside China — is not a charity. AZ runs rigorous pipeline triage. They chose to pay because they either see scientific merit in a pan-KRAS program, or because Jacobio's established KRAS commercial infrastructure in China gives JAB-23E73 a faster path to market than they could build alone. Both interpretations are favourable. The US$1.9 billion in milestone payments that follow is contingent on AZ executing global trials — real money only if AZ is willing to spend it, which itself signals conviction.
- 02 The NRDL listing is the starting gun, not the finish line. Specialty oncology drugs in China typically take 12 to 24 months after NRDL inclusion for hospital formularies to activate, physicians to accumulate experience, and volume to ramp. The 7-month sales figure reflects the first weeks of that curve. The first decisive read on trajectory is H1 2026 drug revenue — due in Jacobio's interim results around July–August 2026. That single number resolves the most important open question in this thesis.
- 03 Net cash of HK$1.73 billion gives Jacobio 11 years of runway. Against an annual burn rate of approximately RMB 146 million, the company does not need to raise capital to complete the Phase III, to file for regulatory approval, or to build out its commercial team. In a scenario where everything goes wrong clinically and commercially, the floor is the cash — not zero.
What the Company Is Worth
Sum-of-parts, not P/E — the company has no earnings yet.
Net cash is mark-to-market: HK$1.73 billion, approximately HK$2.20 per share across 787 million shares outstanding. Glecirasib's peak China revenue, priced at RMB 3 000–5 000 per patient per month after NRDL negotiation and applied to a population of 80 000–120 000 eligible patients per year, implies peak annual revenue of RMB 200–350 million. At 5× price-to-sales — conservative for a commercial-stage China specialty oncology drug — that supports approximately HK$1.25 billion.
Risk-adjusted optionality layers on top: the combo Phase III at 30% probability of first-line approval adds approximately HK$1.2 billion. AZ milestones, discounted at 35% probability of achieving major commercialisation hurdles, contribute approximately HK$1.6 billion.
| Component | Basis | Value (HKD) |
|---|---|---|
| Net cash (post-AZ payment) | Mark-to-market | 1.73B |
| Glecirasib China (5× P/S, peak RMB 250M) | Conservative NRDL-priced | ~1.25B |
| Combo Phase III optionality (30% prob.) | Risk-adjusted | ~1.20B |
| AZ milestones (35% prob.) | Risk-adjusted NPV | ~1.60B |
| ADC pipeline | Early stage — minimal current value | ~0.20B |
| Total | ~HK$6.0B → ~HK$7.60/share | ~6.0B |
| Current price | April 11, 2026 | HK$7.22 |
The base case barely moves from today's price. The bull case — combo Phase III success with glecirasib ramp confirming — targets HK$12–16. The bear case is the cash floor: HK$3–4. That asymmetry is the structure of the trade, not the valuation itself.
Risks We Are Not Downplaying
Two risks are documented. Neither is hypothetical.
Wang Yinxiang, CEO, bought HK$96 million of his own company between July and September 2025 at an average price of HK$8.56. Since then: zero additional purchases. He sits at −16% on his cost basis at today's HK$7.22 and has not added below his own entry. A CEO who believes his bull case adds at a discount. He has not done so in six months. The corporate buyback reinforces this: the board authorised a HK$100 million repurchase programme — and has deployed HK$3.2 million, 3.2% of the envelope.
H1 2026 glecirasib revenue is the single most important observable in this thesis. Below RMB 10 million — half the annualised pace of the first 7-month period — would signal that hospital adoption is blocked or the patient pool is smaller than modelled. That triggers a re-evaluation, not a hold. Separately, a Phase III futility determination or Data Safety Monitoring Board halt removes the largest source of bull-case value and pushes the stock toward cash floor levels. This risk is binary by nature and cannot be hedged through position sizing alone.
The KRAS G12C market ceiling in China — approximately RMB 200–350 million peak revenue at full penetration — also means that glecirasib alone does not support HK$12–16. The bull case requires two things to work: drug ramp confirmation and Phase III success. That correlation makes the thesis harder, not easier, than a single-catalyst bet.
The Decision
This is not a growth investment. The thesis does not rest on "Jacobio will accelerate." It rests on a specific event sequence: glecirasib ramp confirmation in H1 2026, followed by Phase III readout that expands the label. One without the other produces a base case near current price. Both together produce a material re-rating.
Given that structure, call options — HK$10–11 strike, December 2026 expiry, purchased 4–6 weeks before H1 2026 results — are the more precise instrument than common equity for a new position. They cap the loss to premium paid if glecirasib disappoints, while offering full participation if the ramp confirms. For equity holders already in: no reason to exit ahead of July–August 2026. The cash floor holds the downside.
| Scenario | Observable Signal | Price Implication |
|---|---|---|
| Bull | H1 2026 glecirasib ≥ RMB 20M + Phase III on schedule (interim results, Jul–Aug 2026) | HK$12–16 |
| Neutral | H1 2026 glecirasib RMB 10–20M, Phase III continuing | HK$7.60–9.50 — hold |
| Bear | H1 2026 glecirasib < RMB 10M, or Phase III DSMB halt, or AZ deprioritises JAB-23E73 | HK$3–4 — exit |
Three signals would invalidate the thesis outright: H1 2026 drug revenue below RMB 10 million; AZ deprioritising JAB-23E73 or acquiring a superior pan-KRAS asset externally; or a Phase III halt for futility. Until one of these appears, the market has priced a biotech at cash minus a small discount. The pipeline has not failed. AstraZeneca's cheque has not bounced.